Clinical Pre-screening Protocol for Ovarian Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Ovarian Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/20/2019 |
| Start Date: | March 2019 |
| End Date: | March 2022 |
| Contact: | Christin Whalen, MD |
| Email: | christin_whalen@DFCI.HARVARD.EDU |
| Phone: | +617-582-1138 |
The pre-screening study is established to pre-screen tumor samples from ovarian cancer
patients to identify if they, at a later stage of their disease, will benefit from treatment
with any investigational cancer drugs available to Oncology Venture, when these drugs are
approved for future clinical studies by local authorities.
patients to identify if they, at a later stage of their disease, will benefit from treatment
with any investigational cancer drugs available to Oncology Venture, when these drugs are
approved for future clinical studies by local authorities.
Inclusion Criteria:
- Patients with histological confirmed epithelia ovarian cancer
- Relapse after 2 or more chemotherapies for ovarian cancer
- FFPE tumor tissue available
Exclusion Criteria:
- Other primary malignancy within the last 5 years prior to enrolment
We found this trial at
1
site
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
